Gastroenterology

Long-term childhood outcomes were comparable in biologic-exposed and unexposed infants born to mothers with inflammatory bowel disease.

May describes differences between colorectal cancer screening tests and which might be right for patients based on their preferences and values.

May discusses currently available NITs for colorectal cancer screening, the continued importance of colonoscopy, and the emergence of blood-based tests.

Our Q1 recap for gastroenterology spotlights regulatory updates, clinical trial data, and new research and guidance about colorectal cancer screening.

Investigators encourage further study of treatment and therapy methods for childhood IBD.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

Examining recent developments in ASUC management, including predictive markers for colectomy, new treatment approaches, and ongoing challenges.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

In the final segment of this 6-part RX Review, experts discuss key concepts from the USMSTF guidance where evidence is limited.

In the fifth segment of this 6-part RX Review, experts discuss areas where more research is needed on bowel preparation for colonoscopy.

In the fourth segment of this 6-part RX Review, experts discuss potential barriers to implementation of the USMSTF guidance and compliance challenges.

In the third segment of this 6-part RX Review, experts discuss key updates from the previous 2014 iteration of the USMSTF guidance.

In the second segment of this 6-part RX Review, experts discuss benchmarks for assessing adequate bowel preparation and the need for standardized scoring.

In the opening segment of this 6-part RX Review, experts discuss new USMSTF guidance on bowel preparation for colonoscopy.

Patients with celiac disease had a 2-fold greater risk of developing a chronic liver disease and experiencing major adverse liver outcomes.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

The gastroenterology month in review spotlights GI FDA news, research about colorectal cancer and alcohol complications, and new data for mirikizumab.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

In adolescents and young adults, gastrointestinal complications from alcohol are increasing at greater rates than other organ systems.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

The Fast Track Designation was granted to Biodexa Pharmaceuticals’ eRapa based on phase 2 data showing its safety and tolerability in adults with FAP.

Study findings suggest children with documented SARS-CoV-2 infection face an increased risk of GI tract symptoms than those without the infection.